Livforsakringsbolaget Skandia, Omsesidigt Biomarin Pharmaceutical Inc Transaction History

Livforsakringsbolaget Skandia, Omsesidigt

$1.72 Billion
Q3 2024

A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 1,720 shares of BMRN stock, worth $114,603. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,720

Previous 320 437.5%

Holding current value

$114,603

Previous $26,000 361.54%

% of portfolio

0.01%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	BUY	$69.02 - $93.84 $96,628 - $131,376	1,400 Added 437.5%	1,720 $120,000
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $90,376 - $106,634	-1,100 Reduced 77.46%	320 $27,000
Q2 2022 Aug 16, 2022	SELL	$71.48 - $86.85 $157,256 - $191,070	-2,200 Reduced 60.77%	1,420 $118,000
Q2 2021 Jul 13, 2021	BUY	$75.51 - $84.79 $135,918 - $152,622	1,800 Added 98.9%	3,620 $302,000
Q4 2019 Jan 28, 2020	SELL	$64.27 - $86.37 $32,134 - $43,185	-500 Reduced 21.55%	1,820 $154,000
Q2 2019 Jul 19, 2019	BUY	$80.35 - $93.9 $56,244 - $65,730	700 Added 43.21%	2,320 $199,000
Q3 2018 Oct 26, 2018	SELL	$93.92 - $105.72 $178,448 - $200,868	-1,900 Reduced 53.98%	1,620 $157,000
Q1 2018 Apr 11, 2018	BUY	$77.67 - $92.63 $69,903 - $83,367	900 Added 34.35%	3,520 $186,000
Q4 2017 Jan 18, 2018	SELL	$80.76 - $95.13 $56,532 - $66,591	-700 Reduced 21.08%	2,620 $234,000
Q3 2017 Oct 12, 2017	BUY	$80.6 - $94.95 $267,592 - $315,234	3,320	3,320 $309,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Livforsakringsbolaget Skandia, Omsesidigt, based on Form 13F filings with the SEC.

News

Stay updated on Livforsakringsbolaget Skandia, Omsesidigt with notifications on news.

Account

Livforsakringsbolaget Skandia, Omsesidigt Biomarin Pharmaceutical Inc Transaction History